(Q38492826)

3 September 2017

title

Evaluation of a Pharmacist-Directed Vancomycin Dosing and Monitoring Pilot Program at a Tertiary Academic Medical Center (English)

1 reference

3 September 2017

1 reference

Kathleen A Marquis

1

1 reference

3 September 2017

Jeremy R DeGrado

2

1 reference

3 September 2017

Stephanie Labonville

3

1 reference

3 September 2017

David W Kubiak

4

1 reference

3 September 2017

Paul M Szumita

5

1 reference

3 September 2017

language of work or name

English

0 references

publication date

19 May 2015

1 reference

Annals of Pharmacotherapy

3 September 2017

published in

1 reference

3 September 2017

volume

49

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

1009-1014

1 reference

Symposium on antimicrobial agents--Part XII. Vancomycin

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

The pharmacokinetic and pharmacodynamic properties of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Practice guidelines for the management of bacterial meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Outcome assessment of minimizing vancomycin monitoring and dosing adjustments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Pharmacokinetics of vancomycin in patients with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Implementation and evaluation of vancomycin nomogram guidelines in a computerized prescriber-order-entry system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028015587900

21 January 2018

Identifiers

DOI

10.1177/1060028015587900

1 reference

3 September 2017

1 reference